natgillin/translations-raw huggingface dataset:
It is important to ensure that the product is applied to an area where the dog cannot lick it off, and to ensure that other animals do not lick the treatment sites following application. 
Zdravljeno žival je Dokler se mesto nanosa ne posuši je potrebno zdravljeno žival ločiti od preostalih živali.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” 
BESEDILO “ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM ” Zdravilo shranjujte nedosegljivo otrokom.
Date of first authorisation: 22 January 2001 Date of latest renewal: 29 November 2010 
Datum prve odobritve: 22. januar 2001 Datum zadnjega podaljšanja: 29. november 2010
The potential risk for humans is unknown. 
Potencialno tveganje za ljudi ni znano.
n = 38 n = 39 n = 36 n = 36 n = 37 
n = 38 n = 39 n = 36 n = 36
This can be due to the high dosages usually used in this population. 
To je lahko posledica visokih odmerkov, ki se običajno uporabijo pri tej populaciji.
If this happens, do not drive or use any tools or machines. 
Če se to zgodi, ne upravljajte vozil, orodja ali strojev.
Before having an operation 
Pred operacijo
There were 77 subjects enrolled into the first study and 109 subjects into the second. 
V prvi študiji je bilo vključenih 77 oseb, v drugi pa 109 oseb.
This means it is essentially “sodium free”. 
To pomeni, da je v bistvu »brez natrija«.
You may need urgent medical treatment. 
Mogoče boste potrebovali nujno medicinsko zdravljenje.
The risk of spreading of effect is greater than in adults, and more frequently severe. 
Tveganje za širjenje učinka je večje in pogosto bolj resno kot pri odraslih.
Results of comparisons of the primary and secondary efficacy variables are summarised in Table 1. 
Rezultati primerjanja primarnih in sekundarnih variabel učinkovitosti so povzeti v preglednici 1.
Other side effects include: 
Med drugimi neželenimi učinki so:
The available reports indicate that the product has been used in the paediatric population. 
Razpoložljiva poročila kažejo, da je bilo zdravilo uporabljeno pri pediatrični populaciji.
On these scales, scores of 50 indicate no change, 0 much worse, and 100 much better. 
Na teh lestvicah je vrednost 50 pomenila, da ni bilo spremembe, 0 je bilo hudo poslabšanje, 100 pa veliko izboljšanje.
The dosing frequency should therefore be adapted based on the clinical assessment/response of an individual patient. 
Zato je treba pogostnost odmerjanja prilagoditi na podlagi klinične ocene/odziva posameznega bolnika.
The risks, which can include death, may outweigh the potential benefits. 
Tveganje, ki lahko vključuje smrt bolnika, je lahko večje od možnih koristi.
In these studies, the average dosing frequency was approximately every 12 weeks. 
V teh študijah je bila povprečna pogostnost odmerjanja približno vsakih 12 tednov.
In the event of an overdose, general medical supportive measures should be instituted. 
V primeru prevelikega odmerjanja morate uporabiti splošne zdravstvene podporne ukrepe.
This warning includes use in children and in any other indication besides cervical dystonia. 
To opozorilo vključuje uporabo pri otrocih in vsako drugo indikacijo, razen cervikalne distonije.
Wear waterproof gloves and soak up the liquid with an appropriate absorbent. 
Nosite nepremočljive rokavice in popivnajte tekočino z ustreznim absorbentom.
The frequency of these side effects is not known. 
Pogostnost teh neželenih učinkov ni znana.
Intramuscular use. 
Intramuskularna uporaba.
Injections should be repeated as required to maintain good function and minimise pain. 
Injiciranje morate po potrebi tudi ponavljati, da bi zagotovili dobro delovanje in čim bolj zmanjšali bolečine.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
The following information is intended for healthcare professionals only: INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL 
Naslednje informacije so namenjene samo zdravstvenemu osebju: NAVODILA ZA PRIPRAVO IN RAVNANJE Z ZDRAVILOM IN ODLAGANJE
Specifically, these studies showed approximately 19-25% seroconverted within 18 months of initiation of treatment, increasing to approximately 33-44% with up to 45 months of treatment. 
Natančneje rečeno so te študije pokazale, da je približno 19-25 % bolnikov serokonvertiralo v 18 mesecih po uvedbi zdravljenja, ta delež pa se je do 45. meseca zdravljenja zvečal na približno 33-44 %.
General precaution: 
Splošni previdnostni ukrepi:
Very Common 
Zelo pogosti
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}> Other sources of information 
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}> Drugi viri informacij
Case reports are more likely to be serious in children (40%) compared to those in adults and older people (12%), possibly as a result of using an inappropriately high dosage for the child (see section 4.9). 
Večja verjetnost je, da so poročila o primerih resnejša pri otrocih (40 %) v primerjavi z odraslimi in starejšimi ljudmi (12 %), kar je morda posledica uporabe neprimerno/neustrezno visokega odmerka pri otrocih (glejte poglavje 4.9).
You may feel pain at the place where you had the injection, but this should wear off after a few minutes. 
Morda boste čutili bolečino na mestu injiciranja, vendar bi ta po nekaj minutah morala prenehati.
These include dysphagia and breathing difficulties. 
To vključuje disfagijo in težave z dihanjem.
They may happen days to weeks after you have had the injection. 
Lahko se pojavijo več dni do več tednov po injekciji.
Cases of overdose (some with signs of systemic toxicity) have been reported. 
Poročali so o primerih prevelikega odmerjanja (nekaterih z znaki sistemske toksičnosti).
However, the pharmacological characteristics do not indicate any need to adjust the dose. 
Vendar farmakološke lastnosti ne kažejo na to, da bi morali odmerek prilagajati.
The dose resulting in death was 2400 U/kg. 
Smrtni odmerek je bil 2400 E/kg.
The medicinal product is ready to use and no reconstitution is required. 
Zdravilo je pripravljeno za uporabo in rekonstitucija ni potrebna.
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
As with other botulinum toxins spontaneous recovery will occur over a period of time. 
Kot pri drugih botulinskih toksinih čez čas pride do spontanega okrevanja.
In rare cases difficulty in swallowing may be severe and choking is possible. 
V redkih primerih so lahko težave s požiranjem hude in možno je dušenje.
The safety and efficacy of NeuroBloc in children aged less than 18 years have not yet been established. 
Varnost in učinkovitost zdravila NeuroBloc pri otrocih, mlajših od 18 let, še nista dokazani.
Spread of toxin effect 
Širjenje delovanja toksina
An investigation into the consequence of seroconversion showed that the presence of antibodies was not synonymous with a loss of clinical response, and did not have an impact on the overall safety profile. 
Raziskava posledic serokonverzije je pokazala, da prisotnost protiteles ni obvezno pomenila izgube kliničnega odziva in ni vplivala na celoviti varnostni profil.
Animal reproduction studies are insufficient with respect to effects on pregnancy and embryonal/foetal development. 
Študije o vplivu na razmnoževanje pri živalih ne zadoščajo za oceno učinkov na nosečnost in razvoj embrija/ploda.
The safety of NeuroBloc outside the approved indication has not been established. 
Varnost zdravila NeuroBloc zunaj odobrene indikacije ni bila dokazana.
CLINICAL PARTICULARS 4.1 Therapeutic indications 
KLINIČNI PODATKI 4.1 Terapevtske indikacije
TWSTRS-Total 
TWSTRS - Skupno
If you are going to have an operation, please tell your doctor that you have been given NeuroBloc. 
Če boste imeli operacijo, povejte svojemu zdravniku, da ste prejeli zdravilo NeuroBloc.
If you think that the effect of NeuroBloc is too strong or too weak, talk to your doctor. 
Če menite, da je učinek zdravila NeuroBloc premočan ali prešibak, se posvetujte z zdravnikom.
Store in a refrigerator (2°C-8°C). 
Shranjujte v hladilniku (2 °C-8 °C).
However, no pharmacokinetic or Absorption, Distribution, Metabolism and Excretion (ADME) studies have been performed. 
Vendar niso bile opravljene nikakršne farmakokinetične študije ali študije absorpcije, porazdelitve, presnove in izločanja (ADME - Absorption, Distribution, Metabolism and Excretion).
Restricted to hospital use only. 
Dovoljeno samo za uporabo v bolnišnici.
The systemic No Observed Effect Level (NOEL) was shown to be approximately 960 U/kg. 
Sistemska raven brez vidnega učinka (NOEL - No Observed Effect Level) je bila približno 960 E/kg.
SPECIAL WARNINGS THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN 
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
Pharmacotherapeutic group: muscle relaxant, peripherally acting agents, ATC code: M03AX 01. 
Farmakoterapevtska skupina: mišični relaksanti s perifernim delovanjem, oznaka ATC: M03AX 01.
Data from clinical studies suggest that efficacy is dose dependent, but these trials, because they were not powered for a comparison, do not show a significant difference between 5000 U and 10,000 U. Therefore an initial dose of 5000 U may also be considered, but a dose of 10,000 U may increase the likelihood of clinical benefit. 
Podatki iz kliničnih študij kažejo, da je učinkovitost odvisna od odmerka, vendar ta preskušanja, ker niso bila primerjalna, ne kažejo signifikantne razlike med odmerkoma s 5.000 E in 10.000 E. Zato lahko pretehtate uporabo začetnega odmerka s 5.000 E, čeprav lahko odmerek z 10.000 E poveča verjetnost ugodnega kliničnega učinka.
Patient evaluations continued for 16 weeks post injection. 
Bolnike so ocenjevali še 16 tednov po injiciranju.
Recovery usually takes place over a period of time. 
Stanje se navadno sčasoma izboljša.
Placebo 10,000 U Placebo 5000 U 10,000 U 
ocene placebo 10.000 E placebo 5.000 E 10.000 E
Paediatric use (non approved): in children, clinically significant systemic toxicity has occurred at doses approved for the treatment of adult patients. 
Pediatrična uporaba (neodobrena uporaba): pri otrocih se je pri odmerkih, odobrenih za zdravljenje odraslih bolnikov, pojavila klinično pomembna sistemska toksičnost.
If he/she is unavailable seek emergency assistance. 
Če ni dosegljiv, poiščite nujno medicinsko pomoč.
At the end of this period, the product should not be put back in the refrigerator and should be disposed of. 
Po koncu tega obdobja zdravila ne smete spraviti nazaj v hladilnik, ampak ga morate zavreči.
The immunogenicity of NeuroBloc has been evaluated in two clinical studies and an open-label extension study. 
Imunogenost zdravila NeuroBloc so ocenili v dveh kliničnih študijah in odprti podaljšani študiji.
This is because swallowing problems could make you breathe food or liquids into your lungs, which could then cause very serious pneumonia 
Zaradi težav s požiranjem bi namreč lahko vdihnili hrano ali tekočine v pljuča, kar bi lahko potem povzročilo zelo resno pljučnico.
Doses of up to 15,000 U have infrequently resulted in clinically significant systemic toxicity in adults. 
Odmerki do 15.000 E so pri odraslih redko povzročili klinično značilno sistemsko toksičnost.
Further clinical studies and open label follow-up have shown that subjects can continue to respond to NeuroBloc for prolonged periods of time, with some subjects receiving more than 14 treatment sessions over a period of more than 3.5 years. 
Nadaljnje klinične študije in odprte nadaljevalne študije so pokazale, da se bolniki lahko še naprej za dolga časovna obdobja odzivajo na zdravilo NeuroBloc, pri čemer so nekateri bolniki prejeli več kot 14 sej zdravljenja v obdobju več kot 3,5 leta.
The solution is clear and colourless to pale yellow. 
Raztopina je bistra in brezbarvna do bledo rumena.
Adverse reactions seen in all clinical studies are listed below according to MedDRA system organ class and in decreasing frequency which is defined as follows: Very Common (>1/10); Common (>1/100 to <1/10); Uncommon (>1/1000 to <1/100). 
Neželeni učinki iz vseh kliničnih študij so navedeni spodaj in so razdeljeni po organskih sistemih po MedDRA in pogostosti na naslednji način: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1000 do < 1/100).
Development studies in rats and rabbits have shown no evidence of foetal malformations or changes to fertility. 
Študije razvoja pri podganah in kuncih niso pokazale deformacij ploda ali spremembe plodnosti.
Analysis of the TWSTRS sub scales revealed significant effects on the severity of cervical dystonia and its associated pain and disability. 
Analiza podlestvic lestvice TWSTRS je pokazala signifikantne učinke na hudost cervikalne distonije ter z njo povezane bolečine in invalidnosti.
If your doctor suspects that botulism may have occurred, you will be admitted to hospital and your breathing (respiratory function) will be monitored. 
Če vaš zdravnik posumi, da gre za botulizem, boste sprejeti v bolnišnico, kjer bodo spremljali vaše dihanje (respiratorno funkcijo).
NeuroBloc should not be used during pregnancy unless the clinical condition of the woman requires treatment with Botulinum Toxin Type B (see section 5.3). 
Zdravila NeuroBloc ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje z botulinskim toksinom vrste B (glejte poglavje 5.3).
Use immediately if diluted (see section 4.2 and section 6.6). 
Razredčeno zdravilo porabite takoj (glejte poglavje 4.2 in poglavje 6.6).
Caution should be used in patients with bleeding disorders or receiving anticoagulant therapy. 
Previdni morate biti pri bolnikih, ki imajo motnje krvavitve ali se zdravijo z antikoagulanti.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
This is because NeuroBloc can affect the medicines you may be given before a general anaesthetic. 
Zdravilo NeuroBloc namreč lahko vpliva na zdravila, ki vam jih bodo mogoče dali pred splošno anestezijo.
The primary efficacy outcome variable for both studies was the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score (range of possible scores is 0-87) at Week 4. 
Primarna spremenljivka izida učinkovitosti je bila pri obeh študijah skupni rezultat vrednosti Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) (možne vrednosti so v intervalu 0-87) v četrtem tednu.
The excretion of Botulinum Toxin Type B in milk has not been studied in animals. 
Izločanje botulinskega toksina vrste B v mleko ni bilo preučeno na živalih.
Particular caution should be paid to ensure that it is not injected into a blood vessel. 
Potrebna je posebna pozornost, da se zdravilo ne injicira v krvno žilo.
If your swallowing difficulty gets worse or you have choking or breathing problems, see a doctor immediately. 
Če se težave s požiranjem poslabšajo ali če se začnete dušiti ali je dihanje oteženo, pojdite nemudoma k zdravniku.
A decision must be made on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NeuroBloc taking into account the benefit of breast-feeding to the child and the benefit of NeuroBloc therapy to the woman. 
Odločiti se je treba med nadaljevanjem/prenehanjem dojenja in nadaljevanjem/prekinitvijo zdravljenja z zdravilom zdravila NeuroBloc, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja z zdravilom NeuroBloc za mater.
Children (non approved use) and patients with underlying neuromuscular disorders including swallowing disorders are at increased risk of these adverse reactions. 
Pri otrocih (neodobrena uporaba) in bolnikih z nevromuskulaturnimi motnjami, vključno z motnjami požiranja, je tveganje neželenih učinkov še večje.
What you need to know before you use NeuroBloc Do not use NeuroBloc: 
Kaj morate vedeti, preden boste uporabili zdravilo Neurobloc Ne uporabljajte zdravila NeuroBloc:
NeuroBloc contains less than 1 mmol sodium (23 mg) per 10,000 units of NeuroBloc. 
Zdravilo NeuroBloc vsebuje manj kot 1 mmol natrija (23 mg) na 10.000 enot zdravila NeuroBloc.
The presence of antibodies in these studies was assessed using the mouse protection assay (also known as the Mouse Neutralization Assay, MNA). 
Prisotnost protiteles v teh študijah so ocenjevali s testom zaščite miši (ki je znan tudi kot test nevtralizacije pri miših (MNA- Mouse Neutralization Assay).
The total dose was divided between the selected muscles and 1 to 5 injections per muscle were administered. 
Skupni odmerek so razdelili med izbrane mišice in v posamezno dali eno do pet injekcij.
These side effects have sometimes resulted in death and are possibly related to the spread of botulinum toxin to body parts away from the place where the injection is given. 
Ti neželeni učinki se včasih končajo s smrtjo in so mogoče povezani s širjenjem botulinskega toksina v druge telesne dele z mesta, kamor je bila dana injekcija.
The medicinal product was injected on a single occasion into 2 to 4 of the following muscles: splenius capitus, sternocleidomastoid, levator scapulae, trapezius, semispinalis capitus and scalene. 
Zdravilo so ob enem obisku injicirali v dve do štiri od naslednjih mišic: splenius capitis, sternocleidomastoideus, levator scapulae, trapezius, semispinalis capitis in scalenus.
Because of the nature of the product, no animal studies have been carried out to establish the carcinogenic effects of NeuroBloc. 
Zaradi narave zdravila niso bile izvedene študije na živalih, ki bi pokazale karcinogene učinke zdravila NeuroBloc.
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before you are given NeuroBloc. 
Če niste gotovi, ali kaj od zgoraj navedenega velja za vas, se pogovorite s svojim zdravnikom ali farmacevtom, preden vam dajo zdravilo NeuroBloc.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines: aminoglycoside antibiotics for an infection medicines to stop blood clotting, such as warfarin 
Še posebno povejte svojemu zdravniku ali farmacevtu, če jemljete ali ste jemali kateri od naslednjih zdravil: aminoglikozidne antibiotike zaradi okužbe, zdravila za preprečevanje strjevanja krvi, na primer varfarin.
Very common (may affect more than 1 in 10 people) dry mouth difficulty swallowing headache 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): suha usta, oteženo požiranje, glavobol.
Standard tests to investigate the mutagenicity of NeuroBloc have not been performed. 
Standardni testi za raziskovanje mutagenosti zdravila NeuroBloc niso bili opravljeni.
No fertility studies have been performed and it is not known whether NeuroBloc can affect reproduction capacity. 
Študije plodnosti niso bile opravljene in ni znano, ali zdravilo NeuroBloc lahko vpliva na sposobnost razmnoževanja.
NeuroBloc is presented as a solution for injection in a vial that contains 0.5 ml (2500 Units), 1.0 ml (5000 Units) or 2.0 ml (10,000 Units). 
Zdravilo NeuroBloc je na voljo kot raztopina za injiciranje v viali, ki vsebuje 0,5 ml (2.500 enot), 1,0 ml (5.000 enot) ali 2,0 ml (10.000 enot).
A series of clinical studies have been conducted to evaluate the efficacy and safety of NeuroBloc in the treatment of cervical dystonia. 
Opravili so vrsto kliničnih študij, da bi ovrednotili učinkovitost in varnost zdravila NeuroBloc za zdravljenje cervikalne distonije.
However, in clinical studies, NeuroBloc was administered 16 weeks after the injection of Botulinum Toxin Type A. 
Vendar so v kliničnih študijah dajali zdravilo NeuroBloc 16 tednov po injiciranju botulinskega toksina vrste A.
10,000 U 
10.000 E
Patients treated with therapeutic doses may experience exaggerated muscle weakness. 
Bolniki, zdravljeni s terapevtskim odmerkom, lahko čutijo pretirano oslabelost mišic.
Vials should be visually inspected prior to use. 
Pred uporabo viale vizualno preglejte.
For patients with reduced muscle mass the dose should be adjusted according to individual patient need. 
Pri bolnikih z zmanjšano maso mišic morate odmerek prilagoditi njihovim osebnim potrebam.
Solution for injection 1 vial 
raztopina za injiciranje 1 viala
What NeuroBloc is and what it is used for 
Kaj je zdravilo Neurobloc in za kaj ga uporabljamo
In patients with neuromuscular disorders or history of dysphagia and aspiration, botulinum toxins should only be used in an experimental setting under strict medical supervision. 
Pri bolnikih z nevromuskulaturnimi motnjami ali anamnezo disfagije in aspiracije je dovoljeno botulinski toksin uporabljati le v raziskovalnem okolju pod strogim zdravstvenim nadzorom.
Contents of the pack and other information What NeuroBloc contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo NeuroBloc
Elderly No dose adjustment is required in older people ≥ 65 years of age. 
Starejši ljudje V skupini starejših ljudi, starih ≥ 65 let, ni potrebno prilagajanje odmerka.
5000 U 
5.000 E
In the event of an overdose or injection into a muscle that normally compensates for the cervical dystonia, it is conceivable that the dystonia may worsen. 
V primeru prevelikega odmerjanja ali injiciranja v mišico, ki ponavadi kompenzira cervikalno distonijo, se lahko distonija poslabša.
NeuroBloc injection works by reducing or stopping muscle contractions. 
Injekcija zdravila NeuroBloc deluje tako, da zmanjša ali zaustavi krčenje mišic.
The initial dose is 10,000 U and should be divided between the two to four most affected muscles. 
Začetni odmerek je 10.000 E in ga je treba razdeliti med dve do štiri najbolj prizadete mišice.
The primary efficacy assessment was the TWSTRS Total score, and secondary efficacy assessments included VAS assessment of change evaluated by patient and investigator, conducted at 4, 8 and 12 weeks after treatment. 
Primarno učinkovitost so ocenjevali z lestvico celotne TWSTRS, ocenjevanje sekundarne učinkovitosti pa je vključevalo oceno spremembe lestvice VAS, ovrednoteno tako s strani bolnika kot tudi raziskovalca, opravljeno po 4, 8 in 12 tednih zdravljenja.
EU/1/00/166/001 - 2500 U EU/1/00/166/002 - 5000 U EU/1/00/166/003 - 10,000 U 
EU/1/00/166/001 - 2.500 E EU/1/00/166/002 - 5.000 E EU/1/00/166/003 - 10.000 E
NeuroBloc has been approved for the treatment of cervical dystonia only and should not be used to treat anything else. 
Zdravilo NeuroBloc je odobreno samo za zdravljenje cervikalne distonije in ga ne smete uporabiti za zdravljenje ničesar drugega.
The units expressed are Type B Units, which are not interchangeable with the units used to express the potency of other Botulinum toxin preparations. 
Enote, v katerih je izražena jakost, so enote vrste B, ki niso zamenljive z enotami, ki se uporabljajo za izražanje jakosti drugih pripravkov botulinskega toksina.
These units are not interchangeable with the units used to express the potency of other botulinum toxin preparations (see section 4.4). 
Teh enot ne smete zamenjati z enotami, ki se uporabljajo za izražanje jakosti drugih pripravkov botulinskega toksina (glejte poglavje 4.4).
Pre-Existing neuromuscular disorders 
Obstoječe živčnomišične bolezni
The initial dose of 10,000 U should be divided between the two to four most affected muscles. 
Začetni odmerek 10.000 E je treba razdeliti med dve do štiri najbolj prizadete mišice.